Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle Di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. ChenPaul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain

Research output: Contribution to journalArticlepeer-review

1784 Scopus citations

Abstract

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

Original languageEnglish (US)
Pages (from-to)145-147
Number of pages3
JournalNature medicine
Volume10
Issue number2
DOIs
StatePublished - Feb 2004

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer'. Together they form a unique fingerprint.

Cite this